These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18042685)

  • 21. The role of catalytic cleft and exosite residues of factor VIIa for complex formation with tissue factor pathway inhibitor.
    Iakhiaev A; Ruf W; Rao LV
    Thromb Haemost; 2001 Mar; 85(3):458-63. PubMed ID: 11307815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformational activation of antithrombin by heparin involves an altered exosite interaction with protease.
    Izaguirre G; Aguila S; Qi L; Swanson R; Roth R; Rezaie AR; Gettins PG; Olson ST
    J Biol Chem; 2014 Dec; 289(49):34049-64. PubMed ID: 25331949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells.
    Carneiro-Lobo TC; Schaffner F; Disse J; Ostergaard H; Francischetti IM; Monteiro RQ; Ruf W
    J Thromb Haemost; 2012 Sep; 10(9):1849-58. PubMed ID: 22823596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain.
    Nogami K; Freas J; Manithody C; Wakabayashi H; Rezaie AR; Fay PJ
    J Biol Chem; 2004 Aug; 279(32):33104-13. PubMed ID: 15166225
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lufaxin, a novel factor Xa inhibitor from the salivary gland of the sand fly Lutzomyia longipalpis blocks protease-activated receptor 2 activation and inhibits inflammation and thrombosis in vivo.
    Collin N; Assumpção TC; Mizurini DM; Gilmore DC; Dutra-Oliveira A; Kotsyfakis M; Sá-Nunes A; Teixeira C; Ribeiro JM; Monteiro RQ; Valenzuela JG; Francischetti IM
    Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2185-98. PubMed ID: 22796577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor.
    Carlsson K; Freskgård PO; Persson E; Carlsson U; Svensson M
    Eur J Biochem; 2003 Jun; 270(12):2576-82. PubMed ID: 12787023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Binding studies of the enzyme (factor IXa) with the cofactor (factor VIIIa) in the assembly of factor-X activating complex on the activated platelet surface.
    Ahmad SS; London FS; Walsh PN
    J Thromb Haemost; 2003 Nov; 1(11):2348-55. PubMed ID: 14629468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The functional role of the autolysis loop in the regulation of factor X upon hemostatic response.
    Bonde AC; Lund J; Hansen JJ; Winther JR; Nielsen PF; Zahn S; Tiainen P; Olsen OH; Petersen HH; Bjelke JR
    J Thromb Haemost; 2022 Mar; 20(3):589-599. PubMed ID: 34927362
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the N-terminal epidermal growth factor-like domain of factor X/Xa.
    Kittur FS; Manithody C; Rezaie AR
    J Biol Chem; 2004 Jun; 279(23):24189-96. PubMed ID: 15069066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Definition of a factor Va binding site in factor Xa.
    Rudolph AE; Porche-Sorbet R; Miletich JP
    J Biol Chem; 2001 Feb; 276(7):5123-8. PubMed ID: 11087737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
    Rao LV; Ruf W
    Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zymogenic and enzymatic properties of the 70-80 loop mutants of factor X/Xa.
    Chen L; Manithody C; Yang L; Rezaie AR
    Protein Sci; 2004 Feb; 13(2):431-42. PubMed ID: 14739327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulant activity of a sulfated galactan: serpin-independent effect and specific interaction with factor Xa.
    Glauser BF; Rezende RM; Melo FR; Pereira MS; Francischetti IM; Monteiro RQ; Rezaie AR; Mourão PA
    Thromb Haemost; 2009 Dec; 102(6):1183-93. PubMed ID: 19967150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The tissue factor/factor VIIa/factor Xa complex: a model built by docking and site-directed mutagenesis.
    Norledge BV; Petrovan RJ; Ruf W; Olson AJ
    Proteins; 2003 Nov; 53(3):640-8. PubMed ID: 14579355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX.
    Ndonwi M; Broze GJ; Agah S; Schmidt AE; Bajaj SP
    J Biol Chem; 2007 May; 282(21):15632-44. PubMed ID: 17387172
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
    Kitazawa T; Esaki K; Tachibana T; Ishii S; Soeda T; Muto A; Kawabe Y; Igawa T; Tsunoda H; Nogami K; Shima M; Hattori K
    Thromb Haemost; 2017 Jun; 117(7):1348-1357. PubMed ID: 28451690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition.
    Salemink I; Franssen J; Willems GM; Hemker HC; Lindhout T
    J Biol Chem; 1999 Oct; 274(40):28225-32. PubMed ID: 10497177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alboserpin, a factor Xa inhibitor from the mosquito vector of yellow fever, binds heparin and membrane phospholipids and exhibits antithrombotic activity.
    Calvo E; Mizurini DM; Sá-Nunes A; Ribeiro JM; Andersen JF; Mans BJ; Monteiro RQ; Kotsyfakis M; Francischetti IM
    J Biol Chem; 2011 Aug; 286(32):27998-8010. PubMed ID: 21673107
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stable complex formation between serine protease inhibitor and zymogen: coagulation factor X cleaves the Arg393-Ser394 bond in a reactive centre loop of antithrombin in the presence of heparin.
    Nakatomi Y; Tsuji M; Gokudan S; Hanada-Dateki T; Nakashima T; Miyazaki H; Hamamoto T; Nakagaki T; Tomokiyo K
    J Biochem; 2012 Nov; 152(5):463-70. PubMed ID: 22923734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium enhances heparin catalysis of the antithrombin-factor Xa reaction by a template mechanism. Evidence that calcium alleviates Gla domain antagonism of heparin binding to factor Xa.
    Rezaie AR
    J Biol Chem; 1998 Jul; 273(27):16824-7. PubMed ID: 9642241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.